IL254424A0 - Disubstituted heterocyclic tricyclic compounds - Google Patents

Disubstituted heterocyclic tricyclic compounds

Info

Publication number
IL254424A0
IL254424A0 IL254424A IL25442417A IL254424A0 IL 254424 A0 IL254424 A0 IL 254424A0 IL 254424 A IL254424 A IL 254424A IL 25442417 A IL25442417 A IL 25442417A IL 254424 A0 IL254424 A0 IL 254424A0
Authority
IL
Israel
Prior art keywords
heterocyclic compounds
tricyclic heterocyclic
substituted tricyclic
substituted
compounds
Prior art date
Application number
IL254424A
Other languages
English (en)
Hebrew (he)
Inventor
Hai-Yun Xiao
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Original Assignee
Bristol Myers Squibb Co
Xiao Hai Yun
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Xiao Hai Yun, T G Murali Dhar, Jingwu Duan, Bin Jiang, Andrew J Tebben filed Critical Bristol Myers Squibb Co
Publication of IL254424A0 publication Critical patent/IL254424A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
IL254424A 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds IL254424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
IL254424A0 true IL254424A0 (en) 2017-11-30

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254424A IL254424A0 (en) 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds

Country Status (14)

Country Link
US (1) US10189840B2 (enExample)
EP (1) EP3271360B1 (enExample)
JP (1) JP6793657B2 (enExample)
KR (1) KR102654709B1 (enExample)
CN (1) CN107635993B (enExample)
AU (1) AU2016233288A1 (enExample)
BR (1) BR112017019773A2 (enExample)
CA (1) CA2980159A1 (enExample)
EA (1) EA032315B1 (enExample)
ES (1) ES2797805T3 (enExample)
IL (1) IL254424A0 (enExample)
MX (1) MX2017011434A (enExample)
SG (1) SG11201707469WA (enExample)
WO (1) WO2016149436A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
US10112944B2 (en) 2015-03-18 2018-10-30 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of TNF
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
EP3286195A1 (en) 2015-04-17 2018-02-28 AbbVie Inc. Indazolones as modulators of tnf signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EA201890421A1 (ru) 2015-08-03 2018-07-31 Бристол-Маерс Сквибб Компани Циклические соединения, пригодные в качестве модуляторов tnf-альфа
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018167176A1 (en) 2017-03-15 2018-09-20 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
EP0963371B1 (en) 1997-02-25 2003-05-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
ATE311385T1 (de) * 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
CA2474850A1 (en) 2002-01-31 2003-08-07 Daiichi Pharmaceutical Co., Ltd. Imidazo[1,2-a]pyridine derivatives
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
ATE538120T1 (de) * 2007-06-26 2012-01-15 Sanofi Sa Regioselektive, metallkatalysierte synthese annelierter benzimidazole und azabenzimidazole
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102438660A (zh) 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CA2874303C (en) * 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
ES2809535T3 (es) 2013-12-09 2021-03-04 UCB Biopharma SRL Derivados de imidazopiridina como moduladores de la actividad de TNF
DK3204386T3 (da) 2014-10-06 2021-05-25 Signal Pharm Llc Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
US10112944B2 (en) 2015-03-18 2018-10-30 Bristol-Myers Squibb Company Heterocyclic compounds useful as inhibitors of TNF

Also Published As

Publication number Publication date
EA032315B1 (ru) 2019-05-31
SG11201707469WA (en) 2017-10-30
US20180111936A1 (en) 2018-04-26
EP3271360A1 (en) 2018-01-24
JP2018508553A (ja) 2018-03-29
KR20170129810A (ko) 2017-11-27
WO2016149436A1 (en) 2016-09-22
AU2016233288A1 (en) 2017-11-09
EP3271360B1 (en) 2020-04-22
CA2980159A1 (en) 2016-09-22
CN107635993A (zh) 2018-01-26
US10189840B2 (en) 2019-01-29
KR102654709B1 (ko) 2024-04-03
JP6793657B2 (ja) 2020-12-02
EA201792034A1 (ru) 2018-03-30
CN107635993B (zh) 2020-05-22
ES2797805T3 (es) 2020-12-03
BR112017019773A2 (pt) 2018-05-15
MX2017011434A (es) 2018-01-25

Similar Documents

Publication Publication Date Title
ZA201807249B (en) Heterocyclic compound
SG11201605417QA (en) Heterocyclic compounds
PT3498693T (pt) Composto heterocíclico
IL248991A0 (en) Converted dihydroisoquinolinone compounds
IL247018A0 (en) Heterocyclic compound
IL253361A0 (en) A tricyclic spiro compound
IL285105A (en) Heterocyclic compound
SG11201707469WA (en) Substituted tricyclic heterocyclic compounds
IL257501B (en) Compounds containing heterocyclic tricyclic compounds
IL262448B (en) Disubstituted heterocyclic bicyclic compounds
IL254890A0 (en) The tercyclic compound
HUE049482T2 (hu) Új heterociklusos vegyület
IL254320A0 (en) organic compounds
IL249907A0 (en) Tricyclic substances containing a triazole ring
GB201521758D0 (en) Organic compounds
GB201501824D0 (en) Organic compounds
HUP1700522A1 (hu) Triciklusos vegyületek
GB201417043D0 (en) Novel compounds